The New York Times reports:
The Food and Drug Administration is on the verge of announcing one of its most contentious decisions in years: the fate of an Alzheimer’s drug that could be the first treatment approved after nearly two decades of failed efforts to find ways to curb the debilitating disease.
On Monday, the agency will rule on the drug, aducanumab, which aims to slow progression of memory and thinking problems early in the disease.
If approved, it would be the first new Alzheimer’s medication since 2003 and the first treatment on the market that attacks the disease process rather than just easing symptoms.
Read the full article. The drug has faced opposition from some Alzheimer’s experts and the FDA’s own advisory committee, who says its efficacy has not been demonstrated.
Everyone wants a new Alzheimer’s treatment. But not everyone thinks the F.D.A. should approve a drug with a rollercoaster history on Monday. Says one Alzheimer’s doctor: “I want an effective drug to prescribe to my patients, but this is not the drug.” https://t.co/eaMqlH9blG
— NYT Health (@NYTHealth) June 5, 2021